Japan Lifeline to buy US ablation-tool developer with no reported revenue, up to $4mn on an earn-out
Japan Lifeline plans to pay up to $4.73mn, including a $4mn earn-out, for Cross Vascular, an FDA-cleared developer with no revenue reported for 2023 to 2025, and to inject another $7.27mn to pay its debts and fund operations.